These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 21040725)

  • 21. HCV core antigen as an alternate test to HCV RNA for assessment of virologic responses to all-oral, interferon-free treatment in HCV genotype 1 infected patients.
    Rockstroh JK; Feld JJ; Chevaliez S; Cheng K; Wedemeyer H; Sarrazin C; Maasoumy B; Herman C; Hackett J; Cohen DE; Dawson GJ; Cloherty G; Pawlotsky JM
    J Virol Methods; 2017 Jul; 245():14-18. PubMed ID: 28359920
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Viral clearance or persistence after acute hepatitis C infection: interim results from a prospective study.
    Guobuzaite A; Chokshi S; Balciūniene L; Voinic A; Stikleryte A; Zagminas K; Ambrozaitis A; Naoumov N
    Medicina (Kaunas); 2008; 44(7):510-20. PubMed ID: 18695347
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Induction of IgA and sustained deficiency of cell proliferative response in chronic hepatitis C.
    Amador-Cañizares Y; Alvarez-Lajonchere L; Guerra I; Rodríguez-Alonso I; Martínez-Donato G; Triana J; González-Horta EE; Pérez A; Dueñas-Carrera S
    World J Gastroenterol; 2008 Nov; 14(44):6844-52. PubMed ID: 19058312
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Human cytomegalovirus infection inhibits response of chronic hepatitis-C-virus-infected patients to interferon-based therapy.
    Bader el-Din NG; Abd el-Meguid M; Tabll AA; Anany MA; Esmat G; Zayed N; Helmy A; el-Zayady AR; Barakat A; el-Awady MK
    J Gastroenterol Hepatol; 2011 Jan; 26(1):55-62. PubMed ID: 21175794
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antiviral effect of ribavirin in early non-responders to interferon monotherapy assessed by kinetics of hepatitis C virus RNA and hepatitis C virus core antigen.
    Lunel F; Veillon P; Fouchard-Hubert I; Loustaud-Ratti V; Abergel A; Silvain C; Rifflet H; Blanchi A; Causse X; Bacq Y; Payan C;
    J Hepatol; 2003 Nov; 39(5):826-33. PubMed ID: 14568267
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Presence of hepatitis C virus (HCV)-RNA in peripheral blood mononuclear cells in HCV serum negative patients during interferon and ribavirin therapy.
    Januszkiewicz-Lewandowska D; Wysocki J; Pernak M; Nowicka K; Zawada M; Rembowska J; Lewandowski K; Mańkowski P; Nowak J
    Jpn J Infect Dis; 2007 Feb; 60(1):29-32. PubMed ID: 17314422
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chronic hepatitis C virus infection in renal transplant: treatment and outcome.
    Sharma RK; Bansal SB; Gupta A; Gulati S; Kumar A; Prasad N
    Clin Transplant; 2006; 20(6):677-83. PubMed ID: 17100715
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hepatitis C virus-multispecific T-cell responses without viremia or seroconversion among Egyptian health care workers at high risk of infection.
    Abdelwahab SF; Zakaria Z; Sobhy M; Rewisha E; Mahmoud MA; Amer MA; Del Sorbo M; Capone S; Nicosia A; Folgori A; Hashem M; El-Kamary SS
    Clin Vaccine Immunol; 2012 May; 19(5):780-6. PubMed ID: 22441392
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluating the Role of Cellular Immune Responses in the Emergence of HCV NS3 Resistance Mutations During Protease Inhibitor Therapy.
    Abdel-Hameed EA; Rouster SD; Ji H; Ulm A; Hetta HF; Anwar N; Sherman KE; Shata MT
    Viral Immunol; 2016 May; 29(4):252-8. PubMed ID: 26885675
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Virus-specific T-cell responses associated with hepatitis C virus (HCV) persistence in the liver after apparent recovery from HCV infection.
    Quiroga JA; Llorente S; Castillo I; Rodríguez-Iñigo E; López-Alcorocho JM; Pardo M; Carreño V
    J Med Virol; 2006 Sep; 78(9):1190-7. PubMed ID: 16847959
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Transient loss of T-cell reactivity in a patient with hepatitis C virus reinfection.
    Düesberg U; Geulen O; Schneiders AM; Kaiser R; Brackmann HH; Matz B; Sauerbruch T; Spengler U
    Digestion; 2001; 64(1):66-70. PubMed ID: 11549839
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chronic hepatitis C responds poorly to combination therapy in chronic hepatis B carriers.
    Senturk H; Tahan V; Canbakan B; Uraz S; Ulger Y; Ozaras R; Tabak F; Mert A; Ozbay G
    Neth J Med; 2008 May; 66(5):191-5. PubMed ID: 18490796
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differences in hepatitis C virus (HCV)-specific CD8 T-cell phenotype during pegylated alpha interferon and ribavirin treatment are related to response to antiviral therapy in patients chronically infected with HCV.
    Caetano J; Martinho A; Paiva A; Pais B; Valente C; Luxo C
    J Virol; 2008 Aug; 82(15):7567-77. PubMed ID: 18480446
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Utility of enzyme-linked immunosorbent assays to test core antigen in the diagnosis and antiviral therapy management of hepatitis C virus infections.
    Wang L; Chen W; Xi W; Feng J; Dang P; Ma Y; Yu Y
    J Med Virol; 2017 Jul; 89(7):1235-1240. PubMed ID: 27958657
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term follow up of sustained viral response after treatment of hepatitis C with pegylated interferon alpha-2a in hemodialysis patients.
    Dzekova P; Asani A; Selim G; Gelev S; Trajceska L; Amitov V; Selja N; Zabzun M; Mena S; Gaseva M; Sikole A
    Int J Artif Organs; 2009 Mar; 32(3):180-4. PubMed ID: 19440994
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Probable reinfection with hepatitis C virus in a chronic hepatitis C patient with a sustained response to combination therapy.
    Kao JH; Lai MY; Chen PJ; Chen DS
    J Formos Med Assoc; 2001 Dec; 100(12):824-8. PubMed ID: 11802523
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Direct evidence for immunomodulatory properties of ribavirin on T-cell reactivity to hepatitis C virus.
    Rigopoulou EI; Abbott WG; Williams R; Naoumov NV
    Antiviral Res; 2007 Jul; 75(1):36-42. PubMed ID: 17210188
    [TBL] [Abstract][Full Text] [Related]  

  • 38. GB virus C (GBV-C) infection in patients with chronic hepatitis C. Influence on liver disease and on hepatitis virus behaviour: effect of interferon alfa therapy.
    Pawlotsky JM; Roudot-Thoraval F; Muerhoff AS; Pellerin M; Germanidis G; Desai SM; Bastie A; Darthuy F; Rémiré J; Zafrani ES; Soussy CJ; Mushahwar IK; Dhumeaux D
    J Med Virol; 1998 Jan; 54(1):26-37. PubMed ID: 9443106
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Loss of virus-specific T-cell responses in HCV exposed uninfected injection drug users with drug rehabilitation.
    Thurairajah PH; Hegazy D; Demaine A; Kaminski ER; Cramp ME
    J Infect Dis; 2011 Mar; 203(6):847-53. PubMed ID: 21343150
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Both Hepatitis C Virus-Specific T Cell Responses and IL28B rs12979860 Single-Nucleotide Polymorphism Genotype Influence Antihepatitis C Virus Treatment Outcome in Patients with Chronic Hepatitis C.
    Benito JM; García-Samaniego J; García M; Madejón A; Martín-Carbonero L; Cabello A; Álvarez B; Górgolas M; Rallón N
    J Interferon Cytokine Res; 2017 Jun; 37(6):278-286. PubMed ID: 28440692
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.